Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial.

@article{Kaitani2016EfficacyOA,
  title={Efficacy of Antiarrhythmic Drugs Short-Term Use After Catheter Ablation for Atrial Fibrillation (EAST-AF) trial.},
  author={Kazuaki Kaitani and Koichi Inoue and Atsushi Kobori and Yuko Nakazawa and Tomoya Ozawa and Toshiya Kurotobi and Itsuro Morishima and Fumiharu Miura and Tetsuya Watanabe and Masaharu Masuda and Masaki Naito and Hajime Fujimoto and Taku Nishida and Yoshio Furukawa and Takeshi Shirayama and Mariko Tanaka and Katsunori Okajima and Takenori Yao and Yasuyuki Egami and Kazuhiro Satomi and Takashi Noda and Koji Miyamoto and Tetsuya Haruna and Tetsuma Kawaji and Takashi Yoshizawa and Toshiaki Toyota and Mitsuhiko Yahata and Kentaro Nakai and Hiroaki Sugiyama and Yukei Higashi and Makoto Ito and Minoru Horie and Kengo Fukushima Kusano and Wataru Shimizu and Shiro Kamakura and Takeshi Morimoto and Takeshi Kimura and Satoshi Shizuta},
  journal={European heart journal},
  year={2016},
  volume={37 7},
  pages={610-8}
}
AIMS Substantial portion of early arrhythmia recurrence after catheter ablation for atrial fibrillation (AF) is considered to be due to irritability in left atrium (LA) from the ablation procedure. We sought to evaluate whether 90-day use of antiarrhythmic drug (AAD) following AF ablation could reduce the incidence of early arrhythmia recurrence and thereby… CONTINUE READING